O'Shaughnessy Asset Management’s Fate Therapeutics FATE Stock Holding History

O'Shaughnessy Asset Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,502	Closed	-$263K	–	1306
2021 Q4	$263K	Sell	4,502 -198	-4%	-$11.2K	﹤0.01%	934
2021 Q3	$279K	Sell	4,700 -130	-3%	-$10.2K	0.01%	878
2021 Q2	$419K	Sell	4,830 -2	-0%	-$161	0.01%	727
2021 Q1	$398K	Sell	4,832 -23	-0.5%	-$2.2K	0.01%	681
2020 Q4	$441K	Buy	4,855 +4,600	+1,804%	+$286K	0.01%	551
2020 Q3	$10K	Hold	255	–	–	﹤0.01%	1355
2020 Q2	$9K	Buy	+255	New	+$7.6K	﹤0.01%	1272
2020 Q1	–	Sell	-255	Closed	-$5K	–	1444
2019 Q4	$5K	Buy	+255	New	+$4.05K	﹤0.01%	1446

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

O'Shaughnessy Asset Management's FATE Position: Q1 2022 in Review

O'Shaughnessy Asset Management sold out of Fate Therapeutics (FATE) in Q1 2022, closing a stake of 4,502 shares — an estimated $263K sold.

O'Shaughnessy Asset Management first reported a position in FATE in Q4 2019 and held it in 8 quarters. The position peaked at $441K in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q1 2022.

O'Shaughnessy Asset Management reported no remaining Fate Therapeutics position as of Q1 2022 after selling out during the quarter.
O'Shaughnessy Asset Management sold 4,502 Fate Therapeutics shares in Q1 2022, an estimated $263K.
O'Shaughnessy Asset Management first reported a position in Fate Therapeutics in Q4 2019 and held it in 8 quarters.
O'Shaughnessy Asset Management's Fate Therapeutics position peaked at $441K in Q4 2020.
250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2022.

Based on O'Shaughnessy Asset Management's 13F filing for Q1 2022, filed 13 May 2022.